المصدر: Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ; SPIRIT III Investigators. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA. 2008 Apr 23;299(16):1903-13. doi: 10.1001/jama.299.16.1903.
Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Caputo R, Xenopoulos N, Applegate R, Gordon P, White RM, Sudhir K, Cutlip DE, Petersen JL; SPIRIT III Investigators. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation. 2009 Feb 10;119(5):680-6. doi: 10.1161/CIRCULATIONAHA.108.803528. Epub 2009 Jan 26.
Lansky AJ, Ng VG, Mutlu H, Cristea E, Guiran JB, Midei M, Newman W, Sanz M, Sood P, Doostzadeh J, Su X, White R, Cao S, Sudhir K, Stone GW. Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: clinical and angiographic results from the SPIRIT III randomized trial. Catheter Cardiovasc Interv. 2009 Nov 1;74(5):719-27. doi: 10.1002/ccd.22067.
SPIRIT III: A Clinical Evaluation of the Investigational Device XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) in the Treatment of Subjects With de Novo Native Coronary Artery Lesions

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT00180479Test

المساهمون: Matt Kiely

المصدر: Tsucha K, Garc-Garc HM, Ong AT, ValglM, AokJ, Rademaker TA, Morel MA, van Es GA, Brug N, Serruys PW. Revg late loss and neotal volumetr measurements a drug-elutg stent trl: analys from the SP FST trl. Catheter Cardvasc terv. 2006 Feb;67(2):188-97. do 10.1002/ccd.20581.
Popma JJ, Tulli M. Spirit First - Another hurdle is cleared. EuroIntervention. 2005 Nov;1(3):260-3. No abstract available.
Serruys PW, Ong AT, Piek JJ, Neumann FJ, van der Giessen WJ, Wiemer M, Zeiher A, Grube E, Haase J, Thuesen L, Hamm C, Otto-Terlouw PC. A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. EuroIntervention. 2005 May;1(1):58-65.
Tsuchida K, Piek JJ, Neumann FJ, van der Giessen WJ, Wiemer M, Zeiher AM, Grube E, Haase J, Thuesen L, Hamm CW, Veldhof S, Dorange C, Serruys PW. One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowings (The SPIRIT FIRST Trial). EuroIntervention. 2005 Nov;1(3):266-72.
SPRITI FIRST: 2-Jahres-ergebnisse. A durable polymer everolimus-eluting stent in de novo coronary narrowings. Richartz B.; Silber S. Herz ( Germany ) June 1, 2006 , 31/4 (359). ISSN: 0340-9937. Language: German
SPIRIT First: A Clinical Evaluation of an Investigational Device. The Abbott XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Native Coronary Artery Lesions

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT00180453Test

Other URLs: http://eurheartj.oxfordjournals.org/cgi/content/abstract/28/13/1583Test

المساهمون: Marie-Helene Bettiol

المصدر: A Study to Evaluate the Safety and Performance of the Dynalink®-E, Everolimus Eluting Peripheral Stent System for Treating Atherosclerotic de Novo or Restenotic Native Superficial Femoral and Proximal Popliteal Artery Lesions

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT00475566Test

المصدر: More MC. XNCE V SP WOMEN clal trl: characteratn of the female populatn undergog stent plantatn. Womens Health (Lond). 2008 Sep;4(5):439-43. do 10.2217/17455057.4.5.439.
A Clinical Evaluation of the XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Women With de Novo Coronary Artery Lesions

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT00496938Test

المساهمون: Boris Jelecic

المصدر: Krone RJ, Johnson L, Noto T. Fe year trends cardc catheteratn: a report from the Regtry of the Socty for Cardc Anggraphy and terventns. Cathet Cardvasc Dgn. 1996 Sep;39(1):31-5. do 10.1002/ccd.1810390102.
Waksman R, Scott NA, Ghazzal ZM, Mays R, Frerhs FA, Petersen JY, Kg SB 3rd. Randomed comparon of flexle versus nonflexle femoral sheaths on patnt comfort after angplasty. Am Heart J. 1996 Jun;131(6):1076-8. do 10.1016/s0002-8703(96)90079-4.
Bogart DB, Bogart MA, Mler JT, Farrar MW, Barr WK, Montgomery MA. Femoral artery catheteratn complatns: a study of 503 consecute patnts. Cathet Cardvasc Dgn. 1995 Jan;34(1):8-13. do 10.1002/ccd.1810340304.
Chrtensen B, Lacarella C, Mann R, Bruhn-Dg B, Meyer S, Wson R. Sandbags do not prevent complatns after catheteratn. Cculatn 90:205, 1994.
Pracyk JB, Wall TC, Longabaugh JP, Te FD, Hochre J, Green C, Cox G, Lee K, Stack RS, Tcheng JE. A randomed trl of vascular hemostas technues to reduce femoral vascular complatns after coronary terventn. Am J Cardl. 1998 Apr 15;81(8):970-6. do 10.1016/s0002-9149(98)00074-5.
Resar JR, Prewt KC, Wolff MR, Blumenthal R, Raqueno JV, Brker JA. Percutaneous translumal coronary angplasty through 6F dgnost catheters: a feasy study. Am Heart J. 1993 Jun;125(6):1591-6. do 10.1016/0002-8703(93)90745-u.
Cragg AH, Nakagawa N, Smh TP, Berbaum KS. Hematoma formatn after dgnost anggraphy: effect of catheter se. J Vasc terv Radl. 1991 May;2(2):231-3. do 10.1016/s1051-0443(91)72287-2.
Waksman R, Kg SB 3rd, Douglas JS, Shen Y, Ewg H, Mueller L, Ghazzal ZM, Wetraub WS. Predtors of gro complatns after balloon and new-deve coronary terventn. Am J Cardl. 1995 May 1;75(14):886-9. do 10.1016/s0002-9149(99)80681-x.
Campeau L. Percutaneous radl artery approach for coronary anggraphy. Cathet Cardvasc Dgn. 1989 Jan;16(1):3-7. do 10.1002/ccd.1810160103.
Kmene F, Laarman GJ, Odekerken D, Slagboom T, van der Wken R. A randomed comparon of percutaneous translumal coronary angplasty by the radl, brachl and femoral approaches: the access study. J Am Coll Cardl. 1997 May;29(6):1269-75. do 10.1016/s0735-1097(97)00064-8.
Bertrand ME, Legrand V, Boland J, Fleck E, Bonnr J, Emmanuelson H, Vrol M, Msault L, Chrch S, Casacc M, NcolL, Oto A, Whe C, Webb-Peploe M, Van Belle E, McFadden EP. Randomed multenter comparon of conventnal antoagulatn versus antlatelet therapy unplanned and electe coronary stentg. The full antoagulatn versus asp and tlope (fantast) study. Cculatn. 1998 Oct 20;98(16):1597-603. do 10.1161/01.c.98.16.1597.
Leon MB, Ba DS, Popma JJ, Gordon PC, Cutl DE, Ho KK, GmbartolomeA, Der DJ, Lasorda DM, Wlms DO, Pocock SJ, Kuntz RE. A clal trl comparg three anthrombot-drug regens after coronary-artery stentg. Stent Antoagulatn Restenos Study vestators. N Engl J Med. 1998 Dec 3;339(23):1665-71. do 10.1056/NEJM199812033392303.
Dk RJ, Popma JJ, Muller DW, Burek KA, Topol EJ. -hospal costs assocted wh new percutaneous coronary deves. Am J Cardl. 1991 Oct 1;68(9):879-85. do 10.1016/0002-9149(91)90403-8.
Krause PB, Kle LW. Uty of a percutaneous collagen hemostas deve: to plug or not to plug? J Am Coll Cardl. 1993 Nov 1;22(5):1280-2. do 10.1016/0735-1097(93)90530-e. No abstract avaable.
Anderson HV, Bertrand M, Whworth HB, Sax FL, Wlerson JT for the Restore vestators. Bleedg rk wh platelet hn usg Tofan: The Restore Trl. Cculatn. 94:553, 1996.
Lcoff AM, Tcheng JE, Mler DP, Booth JE, Montague EA, Topol EJ. Marked enhancement of clal effacy of platelet GP b/ blockade wh c7E3Fab (Abcab) lked to reductn bleedg complatns: Outcome the EPOG and EP trls. Cculatn 94:375, 1996.
Goods CM, L MW, Ja SP, Mathur A, Yadav JS, Al-ShalbKF, Dean LS, er SS, Parks JM, Roub GS. Low molecular weht hepar versus standard hepar partants at hh rk for stent thrombos: Clal outcomes. Cculatn 94:684, 1996.
Ernst S, Kloss R, Schräder R, Kaltenbach M, Swart U, Sanborn TA. medte sealg of arterl puncture ses after catheteratn and PTCA usg a vascular hemostas deve wh collagen: an ternatnal study. Cculatn 84:272, 1991.
Sber S, Dorr R, Muhlg H, Kon U. Sheath pullg medtely after PTCA: comparon of two dferent deployment technues for the hemostat puncture closure deve: a prospecte, randomed study. Cathet Cardvasc Dgn. 1997 Aug;41(4):378-83. do 10.1002/(s1097-0304(199708)41:43.0.co;2-2.
Sber S. Rap hemostas of arterl puncture ses wh collagen patnts undergog dgnost and terventnal cardc catheteratn. Cl Cardl. 1997 Dec;20(12):981-92. do 10.1002/clc.4960201203.
Sber S. Hemostas success rates and local complatns wh collagen after femoral access for cardc catheteratn: analys of 6007 publhed patnts. Am Heart J. 1998 Jan;135(1):152-6. do 10.1016/s0002-8703(98)70356-4.
Hoffer EK, Bloch RD. Percutaneous arterl closure deves. J Vasc terv Radl. 2003 Jul;14(7):865-85. do 10.1097/01.rv0000071086.76348.8e.
Duff DC, Muhleste JB, Allson SB, Horne BD, Fowles RE, Sorensen SG, Revenaugh JR, Ba TL, Lappe DL. Femoral arterl puncture management after percutaneous coronary procedures: a comparon of clal outcomes and patnt satfactn between manual compressn and two dferent vascular closure deves. J vase Cardl. 2001 May;13(5):354-62.
Shammas NW, Rajendran VR, Alldredge SG, Wc WJ, Robken JA, Lew JR, McKney D, Hansen CA, Kabel ME, Harr M, Jer MJ, Bontu PR, Dpel EJ, Labroo A. Randomed comparon of Vasoseal and Angseal closure deves patnts undergog coronary anggraphy and angplasty. Catheter Cardvasc terv. 2002 Apr;55(4):421-5. do 10.1002/ccd.10098.
Ward SR, Casale P, Raymond R, Kussmaul WG 3rd, Spfendorfer C. Effacy and safety of a hemostat puncture closure deve wh early ambulatn after coronary anggraphy. Ang-Seal vestators. Am J Cardl. 1998 Mar 1;81(5):569-72. do 10.1016/s0002-9149(97)00970-3.
Kussmaul WG 3rd, Buchbder M, Whlow PL, Aker UT, Heuser RR, Kg SB, Kent KM, Leon MB, Kolansky DM, Sandza JG Jr. Rap arterl hemostas and decreased access se complatns after cardc catheteratn and angplasty: results of a randomed trl of a novel hemostat deve. J Am Coll Cardl. 1995 Jun;25(7):1685-92. do 10.1016/0735-1097(95)00101-9.
Kapad SR, Raymond R, Knopf W, Jenks S, Chapek A, Ansel G, Rothbaum D, Kussmaul W, Teste P, Reman M, Casale P, Oster L, Spfendorfer C. The 6Fr Ang-Seal arterl closure deve: results from a multember prospecte regtry. Am J Cardl. 2001 Mar 15;87(6):789-91, A8. do 10.1016/s0002-9149(00)01507-1.
A Post-Market, Prospective, Multi-Center, Study to Evaluate Safety and Efficacy of the StarClose™ Vascular Closure System in Patients Who Are Ambulated Early Post-Diagnostic Catheterization

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT00736086Test

المساهمون: Vicki Bebeau, Senior Director of Clinical Research

المصدر: Clinical Registry of the St. Jude Medical Angio-Seal(TM) Evolution(TM) Vascular Closure Device Following Diagnostic and/or Interventional Endovascular Procedures

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT00817349Test

المصدر: A Prospective, Non-randomized, 2 Arm (AP Arm & Omni-Link Elite [OE] Arm-separately Posted as: NCT01396525), Multi-center Clinical Trial to Evaluate the Safety and Efficacy of the Absolute Pro™ Peripheral Self-Expanding Stent System and the Omnilink Elite™ Peripheral Balloon-Expandable Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery. CAUTION: The Omnilink Elite™ Peripheral Balloon-expandable Stent System is an Investigational Device. Limited by Federal (U.S.) Law to Investigational Use Only.

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT00844532Test

المؤلفون: Baim Institute for Clinical Research

المصدر: Comparison of the SUpera® PERipheral System to a Performance Goal Derived From Balloon Angioplasty Clinical Trials in the Superficial Femoral Artery

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT00933270Test

المصدر: XIENCE V/PROMUS Everolimus-Eluting Stent System Japan Post-marketing Surveillance Protocol

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT01086228Test

المؤلفون: Baim Institute for Clinical Research, Bristol-Myers Squibb, Eli Lilly and Company, Daiichi Sankyo

المصدر: XIENCE V® Everolimus Eluting Coronary Stent System USA Post- Approval Study (XIENCE V® USA DAPT Cohort) (XVU-AV DAPT)

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT01106534Test